Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Johns Hopkins University
Age
18–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject must be a man or woman, 18 to 50 years, inclusive
Subject must meet Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) criteria for MDD without psychotic features based on clinician assessment.
Subjects must have undergone 3 or fewer antidepressant trials
Subjects must have moderate to severe depression as determined by a screening Montgomery-Åsberg Depression Rating Scale (MADRS) score of 20 or greater
You may not be if
Subject has a current diagnosis of Bipolar Affective Spectrum Disorder, obsessive compulsive disorder, or a DSM-V personality disorder
Subject has had an incomplete response to more than 3 antidepressant trials
Subject cannot tolerate 60mg DXM as determined by study physician
Subject meets DSM-5 severity criteria for moderate or severe substance or alcohol use disorder within 6 months of screening, excluding caffeine or nicotine
Subject has a current clinical diagnosis of autism, dementia, or intellectual disability
Subject has history of psychosis not attributable to organic/metabolic causes
Subject has a history of serotonin syndrome or sensitivity
Subject has taken venlafaxine or a monoamine oxidase inhibitor (MAOI) within 4 weeks prior to screening
Subject is actively taking an opiate antagonist for any indication
Subject is taking a higher-than-recommended dosage of serotonergic antidepressant \[including but not limited to selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), serotonin partial agonist/reuptake inhibitor (SPARI), serotonin antagonist and reuptake inhibitor (SARI) within 4 weeks prior to screening
Subject is actively suicidal
Subject has participated in another clinical drug trial within 6 months prior to screening
Subject has a history or current signs of liver or renal insufficiency
Subject has a clinically significant condition of any organ system that might adversely impact subject health upon consumption of DXM
Subject has previous history of intolerance to ketamine or its enantiomers
Subject has previous history of incomplete antidepressant response to ketamine or its enantiomers
Subject is currently using DXM for any indication
Clareo Health | Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder
